Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth or ongoing pregnancy · Women undergoing IVF/ICSI cycles
ORT‐based algorithm showed no clear difference in live birth or ongoing pregnancy compared with standard starting dose of FSH (low certainty).
1 finding from 1 review
IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
1 finding from 1 review
IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure
Anticipated high responders: higher showed no clear difference in IU vs 100 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
OHSS · Women undergoing IVF/ICSI cycles
ORT‐based algorithm showed no clear difference in OHSS compared with standard starting dose of FSH (low certainty).
1 finding from 1 review
Clinical pregnancy · Women undergoing IVF/ICSI cycles
ORT‐based algorithm showed no clear difference in clinical pregnancy compared with standard starting dose of FSH (low certainty).
1 finding from 1 review
300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 300/450 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 400/450 IU vs 300 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in IU vs 450 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 100 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in IU vs 100 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
225/200 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in 225/200 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 225 IU · women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure
Anticipated normal responders: higher showed no clear difference in IU vs 225 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with respiratory distress for initial respiratory support
It is very uncertain whether nHFV changes mortality before hospital discharge compared with invasive respiratory therapy (very low certainty).
1 finding from 1 review
Death or chronic lung disease · newborn (term* and preterm) infants with respiratory distress for initial respiratory support
nHFV showed no clear difference in death or chronic lung disease compared with nCPAP used (low certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · newborn (term* and preterm) infants with respiratory distress for initial respiratory support
nHFV showed no clear difference in intraventricular haemorrhage, Papile grade 3/4 compared with nCPAP used (low certainty).
1 finding from 1 review
Neurodevelopmental disability · newborn (term* and preterm) infants with respiratory distress for initial respiratory support
1 finding from 1 review
Mortality before hospital discharge · preterm infants with respiratory distress for initial respiratory support
nHFV showed no clear difference in mortality before hospital discharge compared with nIPPV used (low certainty).
1 finding from 1 review